2026³â 04¿ù 04ÀÏ Åä¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Famenity's Brain Factor-7¢ç Gains Global Momentum as Clinically Validated Ingredient for Cognitive Health

´º½ºÀÏÀÚ: 2026-01-03

SEOUL -- Famenity Co., Ltd., a South Korean research and development company specializing in functional ingredients for health supplements, said that its Brain Factor-7® (BF-7®) is drawing attention among global brands seeking clinical-grade cognitive-support ingredients.

BF-7®, a silk-peptide complex, is backed by over 12 independent human studies across the entire lifespan, from children and students to adults and seniors. The findings collectively confirm BF-7®’s benefits for memory, learning ability, cognitive performance, focus, and mental resilience, establishing BF-7® as one of the most comprehensively validated natural cognitive-health ingredients available today. BF-7® is supported by multiple global regulatory recognitions, led first by its listing as a U.S. FDA New Dietary Ingredient (NDI). It is also licensed through Health Canada (NPN), acknowledged by the Ministry of Food and Drug Safety (MFDS) in Korea as an Individually Recognized Functional Ingredient, and certified Halal, making it suitable for the global market. As demand in North America and Europe shifts toward clean-label, non-stimulant nootropics with real clinical evidence, BF-7® stands out thanks to its derivation: a low-molecular-weight silk fibroin peptide complex refined through Famenity’s proprietary enzymatic hydrolysis.

Recent interest has been further driven by BF-7®’s mechanistic profile. Research indicates that BF-7® strengthens neuronal network functioning, supports acetylcholine modulation, reduces oxidative stress, and helps protect neurons from environmental and psychological stressors—mechanistic advantages increasingly valued by supplement formulators and functional-beverage developers.

Finished products containing BF-7® are already distributed across the United States, Canada, Europe, and Asia, reflecting strong commercial acceptance and global scalability. Beyond BF-7®, Famenity has built a broad portfolio of clinically grounded functional ingredients. These include MS-10®, a patented botanical complex supporting women’s menopausal comfort; MR-10®, a men’s vitality and performance formulation; GinsaMin®, a U.S. FDA NDI-listed ginseng-derived compound; TamiSense® (Live EGF), a premium bioactive solution utilizing live EGF for skin regeneration; YES-10®, a mental-wellness ingredient targeting stress balance; and TEES-10®, a dental and oral-health complex. This diverse ingredient platform—spanning cognitive health, women’s and men’s health, skin renewal, mental wellness, and oral care—highlights Famenity’s position as a science-driven innovator in global functional material development.

The company stated that with the global brain-health market rapidly expanding across all age groups, it remains committed to delivering safe, validated, and industry-ready functional ingredients to international partners.



 Àüü´º½º¸ñ·ÏÀ¸·Î

Radian Arc, VNPT and Blacknut Launch GPU Infrastructure in Vietnam, Enabling Cloud Gaming and AI Services
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services
India: The Up-and-Coming Solar Market
LG Electronics Presents Complete HVAC Solution Lineup Tailored for European Market at MCE 2026
Xsolla expands payment coverage in 18 markets with 6 local methods, helping developers reach new players worldwide
WHOOP Broadens WHOOP Advanced Labs Offering, Announcing a Women¡¯s Health Specialized Blood Biomarker Panel
YouTube Expected to Approach 3 Billion Global Users by 2027 as Netflix Surpasses 1 Billion

 

ePLDT Group Powers Enterprise Transformation, Customer-Centric Innovat...
Takeda, Protagonist: FDA Accepts NDA, Grants Priority Review for Rusfe...
Avanci Launches Wi-Fi Licensing Platform and Inaugural Licensee
Global Cloud Infrastructure Spending Rose 29% in Q4 2025 as Hyperscale...
Avia Establishes Global Trust Center in Singapore
PHCbi Launches LiCellGrow Cell Expansion System to Boost Efficient, Hi...
NTT DOCOMO BUSINESS and Airlinq Form Strategic Partnership for Global ...

 


°øÁö»çÇ×
´º½ºÁö Áß¹®Ç¥±â´Â À½Â÷ Ç¥±â¹æ½Ä '纽ÞÙó¢ ´Ï¿ì½ÃÁö'
º£³×ÇÁ·Ò º£³×ÀÎÅõ Áß¹® Ç¥±â 宝Ò¬ÜØÙÌ 宝Ò¬银öõ(ÜÄÒ¬ÜØ...
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®À¯ºñ Alliuv ä¹备: ä¹êó备, ¾Ë¶ã Althle ä¹÷åìÌ
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¹ÙÀÌ¿ÀÀÌ´Ï Bioini Áß¹® Ç¥±â ù±药研 ù±å·æÚ
¿À½ºÇÁ·Ò Ausfrom 奥ÞÙÜØÙÌ, À£ÇÁ·Ò Welfrom 卫ÜØÙÌ
¿¡³ÊÇÁ·Ò Enerfrom 额ÒöÜØÙÌ ¿¡³ÊÀ¯ºñ Eneruv 额Òöêó备
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØÙÌ ä¹ì³ÜØÙÌ

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..